HIV resistance to antiretroviral drugs: Mechanisms, genotypic and phenotypic resistance testing in clinical practice

Acta Clinica Belgica

Volumn 57, Issue 4, 2002, Pages 191-201

  Blaise, P ^a   Clevenbergh, P ^a   Vaira, D ^a   Moutschen, M ^a   Dellamonica, P ^a  

^a NONE   (Belgium)

Author keywords

Antiretrovirals; Genotypic resistance testing; HIV drug resistance; Phenotypic resistance testing

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL PRACTICE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; TREATMENT FAILURE; VIRUS INFECTION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0036629894     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2002.041     Document Type: Article

References (54)

1. Moutschen M, Nkoghe D, Leonard P, Demonty J. Comment je traite une infection par le HIV. I. Bases pathogéniques des choix thérapeutiques. Rev Med Liège. 1997;52:622-4
2. Moutschen M, Nkoghe D, Leonard P, Demonty J. Comment je traite une infection par le HIV. II. Inhibiteurs nucléosidiques de la transcriptase reverse. Rev Med Liège. 1997;52:750-2
3. Nkoghe D, Moutschen M, Leonard P, Demonty J. Comment je traite une infection par le HIV. III. Les inhibiteurs non nucléosidiques de la transcriptase reverse. Rev Med Liège. 1999;54:909-11
4. Nkoghe D, Moutschen M, Demonty J et le' Groupe de Travail de Liège sur l'Infection par le VIH. Recommandations pour la prise en charge du patient infecté par le HIV. I. L'adolescent et l'adulte. Rev Med Liège. 2000;55:417-23
5. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-60
6. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-73
7. Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count reponse to protease inhibitor therapy in a urban AIDS clinic: Reponse to both initial and salvage therapy. AIDS. 1999;13:F35-43
8. Kuritzkes DR. Clinical Implications of Antiretroviral Resistance. Disponible sur le site "http://HIV.medscape.com/Medscape/HIV/ClinicalMgmt/CM.v13/pnt- CM.v13.htlm" en février 2001
9. Clevenbergh P, Durant J, Garraffo R, Chaillou S, Cua E, Dellamonica P. Les multiples aspects de la résistance du HIV aux antirétroviraux. Méd Mal Infect. 2000;30:551-64
10. Coffin JM. Genetic variation in AIDS viruses. Cell. 1986;46:14
11. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science. 1995;267:483-9
12. Kellam P, Boucher CAB, Tijnagel JMGH, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol. 1994;75:341-51
13. Drusano GL, Bilello JA, Stein DS et al. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178:360-7
14. Rubio A, Gomez-Cano M, Puig T et al. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load. Antivir Ther. 1999;4:45-9
15. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-34
16. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-8
17. Loveday C. Resistance testing in HIV disease management. IAPAC Symposium, October 10, 1999, Vienna, Austria. Available: http://www.iapac.org/conferences/vienna99
18. Japour AJ, Mayers DL, Johnson VA et al. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus type-1 (HIV-1) isolates. Antimicrob Agents Chemother. 1993;37;1095-101
19. Kellam P, Larder BA. Recombinant virus assay: A rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994;38:23-30
20. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-6
21. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News. 1997;5:129-42
22. Richman DD. The implications of drug resistance for strategies of combination antiretroviral chemotherapy. Antiviral Res. 1996;29:31-3
23. Shirasaka T, Kavlick MF, Ueno T et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92:2398-402
24. Iversen AKN, Shafer RW, Wehrly K et al. Mulfidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996;1086-90
25. de Jong JJ, Goudsmit J, Lukashov VV et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS. 1999;13:75-80
26. St Clair MH, Martin JL, Tudor-Williams G et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-9
27. Arion D, Kaushik N, Mc Cormick S et al. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (zidovudine) [Abstract 14]. Antiviral Ther. 1998;3(Suppl 1):13
28. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995;267:988-93
29. Larder BA. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992;36:2664-9
30. th Conference on Retroviruses and Opportunistic Infections; January 30 - February 3, 2000 San Fransisco. California. Abstract 243
31. Swanstrom R, Willis J. Retroviral gene expression: Synthesis, processing and assembly of viral proteins. In: Varmus HE, Coffin J, Hughes S. Retroviruses. Cold Spring Harbor Laboratory Press. 1997;7:263-334
32. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-71
33. Zhang YM, Imamichi H, Imamichi T et al. Drug resistance during indinavir therapy is caused by mutation in the protease gene and in its gag substrate cleavage sites. J Virol. 1997;71:6662-70
34. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther. 2000;5:41-48
35. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-9
36. Clevenbergh P, Durant J, Halfon P et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antiviral Ther. 2000;5:65-70
37. Cohen C, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA3001). Antiviral Ther. 2000;5(Suppl3):67
38. Baxter JD, mayers DL, Wentworth DN et al. Final results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther. 1999;4(suppl1):43. Abstract 61
39. Tural C, Ruiz L, Holtzer C, et al. The potential role of resistance decision support software with or without expert advice in a trial of HIV genotyping versus standard of care - The Havana Trial. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000. Abstract L-10
40. De Luca A, Antinori A, Cingolani A, et al. A prospective, randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6-month results. 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Illinois. Abstract 433
41. Meynard JL, Vray M, Morand-Joubert L, et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088). Antiviral Ther. 2000;5(suppl 3):67-68
42. Melnick D, Rosenthal J, Cameron M, et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. 7th Conference on Retroviruses and Opportunistic Infections. January 30-February 2, 2000; San Francisco, California. Abstract 786
43. Demeter L. Drug resistance and the management of treatment failure. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, California. Abstract S32
44. Clevenbergh P, Blaise P, M Okome N'Koumou, Dellamonica P. Les balbutiements de l'analyse génotypique de la résistance du VIH aux antirétroviraux: La difficile application des performances de la biologie moléculaire à l'efficacité thérapeutique. Med Ther 2002;8:36-41
45. Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-9
46. Schuurman R, Brambilla DJ, De Groot D, et al. Second worldwide evaluation of HIV-1 drug resistance genotyping quality, using the ENVA-2 panel. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, California. Abstract 1168
47. Calvez V. Zidovudine associated resistance mutations can be selected in patients receiving long-term exposure to stavudine. Antiviral Therapy. 1999;4(Supp.1), abstract 38
48. Costagliola D, Descamps D, Calvez V. Presence of thymidineassociated mutations and response to d4T, abacavir and ddI in the control arm of the NARVAL ANRS 088 trial. 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Illinois. Abstract 450
49. Hirsch MS, Conway B, D'Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984-91
50. Soriano V, Ledesma E and the Spanish Drug Resistance Panel. Second spanish consensus on the use of drug resistance testing in clinical practice. AIDS. 2000;2:111-8
51. Prise en charge thérapeutique des personnes infectées par le HIV. Rapport D'experts 1999 sous la Direction du Professeur JF Delfraissy. Paris. Flammarion Médecine-Sciences;1999:35-50
52. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2000;1:76-101
53. Consensus Belge de Thérapeutique et De surveillance du Patient Adulte Infecté par le VIH, Réunion du ler Décembre 2000 Présidée par N. Clumeck (Service des Maladies Infectieuses, CHU St Pierre Bruxelles) et R. Colebundus (Département de Médecine Interne, ITG Anvers)
54. Hirsch MS, Brun-Vézinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-26